New biosimilar for psoriasis enters human testing
NCT ID NCT07254325
First seen Dec 04, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This early-stage study tests a new injectable drug called CMAB015, which is similar to the approved psoriasis treatment Cosentyx. It involves 114 healthy Chinese men to compare how the body processes the drug, its safety, and whether it triggers an immune response. The goal is to see if the new version works just as well as the original.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Jiaotong University School of Medicine
Shanghai, China
Conditions
Explore the condition pages connected to this study.